Tristel plc Reports 10% Revenue Increase to £51.1m and 14% Profit Growth in FY 2026 Trading Update

Robust Revenue Growth Driven by Global Demand for Infection Prevention Solutions

Tristel plc achieved a 10% revenue increase to £51.1m for the fiscal year ended 30 June 2026, up from £46.5m the previous year. This growth reflects strong worldwide demand for the company’s infection prevention products, which leverage proprietary chlorine dioxide chemistry technology. Tristel’s market-leading manual medical device decontamination products and sporicidal surface disinfectants have enabled expansion across hospitals and healthcare facilities in over 40 countries.

The company continues to meet its strategic goal of delivering double-digit revenue growth annually, demonstrating the strength of its product portfolio and ability to enter new markets while consolidating existing ones. With a global footprint comprising 16 subsidiaries and approximately 270 employees, Tristel has the operational infrastructure to support ongoing expansion. Anna Wasyl, Chief Financial Officer and Interim CEO, emphasized strong global demand as a key growth driver and reaffirmed the company’s commitment to international expansion and sustained momentum.

14% Rise in Adjusted Profit Before Tax with EBITDA Margin Above Target

Adjusted profit before tax is projected to reach at least £11.5m for FY 2026, a 14% increase from £10.1m in the prior year. This profit growth outpaces revenue gains, indicating operational leverage and enhanced cost management. The figure slightly exceeds market consensus of £11.4m, reflecting a modest positive surprise for investors.

The adjusted EBITDA margin remains comfortably above the company’s 25% target, underscoring sustained profitability and operational efficiency. Although the exact margin is undisclosed, maintaining this level alongside revenue growth suggests disciplined cost control without sacrificing profitability. The adjusted profit excludes share-based payments, exceptional items, and R&D tax credits, offering a clear view of core trading performance.

Debt-Free Status and Increased Cash Balances Bolster Growth Strategy

Tristel remains debt-free, enhancing financial flexibility and lowering risk. Cash balances rose to £16.0m as of 30 June 2026, up from £12.8m a year earlier—a 25% increase. This cash generation supports organic growth and international expansion without dependence on external financing.

The combination of debt-free status and strong cash flow enables Tristel to invest strategically in growth opportunities. Anna Wasyl noted the company’s financial position "supports continued growth in overseas territories," highlighting international expansion as a key priority. This financial strength is crucial for investors assessing the company’s medium-term growth potential, as it allows investment without diluting shareholder value or incurring debt.

FY 2026 Results Meet Market Expectations and Strategic Targets

The FY 2026 results align with market forecasts and Tristel’s performance objectives. Consensus expected revenues of £51.1m and adjusted profit before tax of £11.4m; the company reported £51.1m revenue and at least £11.5m adjusted profit before tax, meeting or slightly exceeding expectations. This consistency provides investor confidence in management’s forecasting and execution.

Tristel operates under three key targets: double-digit annual revenue growth, maintaining an adjusted EBITDA margin above 25%, and progressive year-on-year dividend growth supported by strong cash generation. The FY 2026 results demonstrate achievement of these goals, with 10% revenue growth described as consistent with targets and reflecting sustained momentum.

Proprietary Chlorine Dioxide Chemistry Drives Competitive Advantage

Tristel’s proprietary chlorine dioxide (ClO2) chemistry underpins its product portfolio and market leadership in manual medical device decontamination. Its sporicidal surface disinfection products offer sustainable alternatives to conventional pre-wetted plastic wipes, addressing multiple infection prevention needs and revenue streams.

This unique chemistry creates a structural competitive advantage, supporting pricing power and the ability to maintain EBITDA margins above 25% while achieving double-digit revenue growth. Distribution across 40+ countries and 16 subsidiaries demonstrates scalability and market acceptance. Investors may view this proprietary technology as a long-term value driver, providing barriers to entry and supporting margin stability.

Cambridge-Based Manufacturing Supports Global Distribution Network

Tristel’s headquarters and manufacturing facility in Snailwell, near Cambridge, UK, serves as the supply hub for hospitals and healthcare providers in over 40 countries via 16 subsidiaries. Proximity to the UK’s science and healthcare cluster facilitates R&D and skilled workforce access.

With approximately 270 employees worldwide, the company balances centralized manufacturing efficiency with local market presence and regulatory compliance. While capacity utilization and capital expenditure plans were not disclosed, 10% revenue growth suggests current capacity meets demand. Investors should watch for future updates on capacity or expansion investments.

Leadership Transition: Chris Lee Appointed CEO

Chris Lee joined Tristel as Chief Executive Officer on 1 August 2026, succeeding Anna Wasyl, who served as Interim CEO while continuing as CFO. Wasyl expressed enthusiasm for Lee’s appointment and anticipates his contribution to driving further growth and international expansion in the new fiscal year. This leadership change coincides with strong financial performance, providing a stable platform for continued success.

The smooth transition and Wasyl’s interim leadership through year-end ensured stability. Investors will monitor Lee’s background and strategic priorities, with emphasis on growth and overseas expansion remaining central objectives.

AIM Listing Facilitates Capital Access and Liquidity

Tristel plc has traded on the London Stock Exchange’s AIM market since 2005 under ticker TSTL. The AIM listing offers access to public capital markets for growth funding and provides shareholder liquidity. AIM’s flexible regulatory framework supports smaller companies while maintaining disclosure and governance standards.

The listing has enabled Tristel’s expansion from a UK-based operation to a global business with 16 subsidiaries across 40+ countries. Regular financial reporting supports investor confidence in the company’s strategic execution. Investors should note that AIM-listed companies may experience higher share price volatility and variable liquidity.

Dividend Growth Supported by Strong Cash Generation

Tristel targets progressive year-on-year dividend growth underpinned by robust cash generation. Cash balances increased from £12.8m to £16.0m in FY 2026, despite investments in growth and expansion. The company’s debt-free status and profitability provide a solid foundation for dividend sustainability.

While specific dividend levels for FY 2026 were not disclosed, the improved cash position suggests dividends remain sustainable and likely to grow with profits. This commitment to dividend growth alongside operational and financial discipline is a key consideration for income-focused investors.

Strategic Healthcare Positioning Supports Long-Term Opportunities

Operating in the infection prevention sector, Tristel addresses critical healthcare needs for safe medical device decontamination and clinical surface disinfection. The sector is characterized by regulatory demands, innovation, and ongoing infection control requirements worldwide. The company’s proprietary chemistry and sustainable product alternatives position it to capture market share amid increasing healthcare system focus on infection prevention and environmental impact reduction.

Heightened regulatory scrutiny and investment following global health events have increased demand for effective infection control solutions. Tristel’s scientifically proven products serve hospitals in over 40 countries, diversifying geographic exposure and reducing reliance on any single market. Investors should monitor regulatory developments and competitive dynamics that could influence market position and pricing power.